Li R, Navab M, Pakbin P, Ning Z, Navab K, Hough G, Morgan TE, Finch CE, Araujo JA, Fogelman AM, Sioutas C, Hsiai T (2013)
Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice
J Lipid Res 54: 1608
Yin F, Lawal A, Ricks J, Fox JR, Larson T, Navab M, Fogelman AM, Rosenfeld ME, Araujo JA (2013)
Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein
Arterioscler Thromb Vasc Biol 33: 1153
Ishikawa K, Navab M, Lusis AJ (2012)
Vasculitis, Atherosclerosis, and Altered HDL Composition in Heme-Oxygenase-1-Knockout Mice
Int J Hypertens 2012: 948203
Navab M, Reddy ST, Anantharamaiah GM, Hough G, Buga GM, Danciger J, Fogelman AM (2012)
D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice
J Lipid Res 53: 437
Camps J, Joven J, Mackness B, Mackness MI, Tawfik DS, Draganov DI, Costa LG, Paragh G, Seres I, Horke S, James RW, Hernandez AF, Reddy ST, Shih DM, Navab M, Rochu D, Aviram M (2011)
Paraoxonase-1 and clopidogrel efficacy
Nat Med 17: 1041
Devarajan A, Bourquard N, Hama S, Navab M, Grijalva VR, Morvardi S, Clarke CF, Vergnes L, Reue K, Teiber JF, Reddy ST (2011)
Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis
Antioxid Redox Signal 14: 341
Vaziri ND, Navab K, Gollapudi P, Moradi H, Pahl MV, Barton CH, Fogelman AM, Navab M (2011)
Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease
J Natl Med Assoc 103: 524
Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, Navab M, Hama S, Hough G, Reddy ST, Soffer D, Rader DJ, Fogelman AM, Schecter A (2011)
Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function
J Lipid Res 52: 361
Vakili L, Hama S, Kim JB, Tien D, Safarpoor S, Ly N, Vakili G, Hough G, Navab M (2010)
The effect of HDL mimetic peptide 4F on PON1
Advances in Experimental Medicine & Biology 660: 167
Narasimha A, Watanabe J, Lin JA, Hama S, Langenbach R, Navab M, Fogelman AM, Reddy ST (2007)
A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors
Prostaglandins Other Lipid Mediat 84: 24
Ng CJ, Bourquard N, Hama SY, Shih DM, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2007)
Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice
Arterioscler Thromb Vasc Biol 27: 1368
Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM (2006)
Mechanisms of disease: proatherogenic HDL--an evolving field
Nat Clin Pract Endocrinol Metab 2: 504
Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM (2006)
Potential clinical utility of high-density lipoprotein-mimetic peptides
Curr Opin Lipidol 17: 440
Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST (2006)
Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2
Journal of Biological Chemistry 281: 29491
Ng CJ, Hama SY, Bourquard N, Navab M, Reddy ST (2006)
Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice
Mol Genet Metab 89: 368
Reddy ST, Anantharamaiah GM, Navab M, Hama S, Hough G, Grijalva V, Garber DW, Datta G, Fogelman AM (2006)
Oral amphipathic peptides as therapeutic agents
Expert Opin Investig Drugs 15: 13
Van Lenten BJ, Reddy ST, Navab M, Fogelman AM (2006)
Understanding changes in high density lipoproteins during the acute phase response
Arterioscler Thromb Vasc Biol 26: 1687
Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, Rader DJ (2005)
Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation
Circulation Research 97: 763
Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman AM (2005)
D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice
Arterioscler Thromb Vasc Biol 25: 1426
Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, Fogelman AM (2005)
Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice
Circulation Research 97: 524
Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM (2005)
Apolipoprotein A-I mimetic peptides
Arterioscler Thromb Vasc Biol 25: 1325
Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, Hough G, Bachini E, Garber DW, Mishra VK, Palgunachari MN, Fogelman AM (2005)
An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice
Arterioscler Thromb Vasc Biol 25: 1932
Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST (2005)
The paraoxonase gene family and atherosclerosis
Free Radic Biol Med 38: 153
Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM (2004)
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice
Circulation 109: 3215
Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM (2004)
Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal
Curr Opin Lipidol 15: 645
Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2004)
Apparent paradox of low-fat healthy diets increasing plasma levels of oxidized low-density lipoprotein and lipoprotein(a)
Arterioscler Thromb Vasc Biol 24: 392
Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Hough G, Wagner A, Nakamura K, Garber DW, Datta G, Segrest JP, Hama S, Fogelman AM (2003)
Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis
Curr Opin Investig Drugs 4: 1100
Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001)
Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein
Journal of Biological Chemistry 276: 44444
Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM (2001)
Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids
Arterioscler Thromb Vasc Biol 21: 542
Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM (2000)
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3
J Lipid Res 41: 1495
La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, Standiford TJ (1999)
On the physiological role(s) of the paraoxonases
Chemico-Biological Interactions 119-120: 379
Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih DM, Fonarow GC (1998)
Paraoxonase and coronary heart disease
Curr Opin Lipidol 9: 319
Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998)
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
Nature 394: 284